Benzinga's Top Ratings Upgrades, Downgrades For June 4, 2021

 

Upgrades

  1. According to Argus Research, the prior rating for Diageo PLC DEO was changed from Hold to Buy. The current stock performance of Diageo shows a 52-week-high of $195.03 and a 52-week-low of $127.12. Moreover, at the end of the last trading period, the closing price was at $192.88.
  2. According to DA Davidson, the prior rating for FormFactor Inc FORM was changed from Neutral to Buy. For the first quarter, FormFactor had an EPS of $0.38, compared to year-ago quarter EPS of $0.33. The stock has a 52-week-high of $52.39 and a 52-week-low of $22.37. At the end of the last trading period, FormFactor closed at $33.31.
  3. According to Stephens & Co., the prior rating for Dick's Sporting Goods Inc DKS was changed from Underweight to Equal-Weight. Dick's Sporting Goods earned $3.79 in the first quarter, compared to $1.21 in the year-ago quarter. At the moment, the stock has a 52-week-high of $101.30 and a 52-week-low of $34.66. Dick's Sporting Goods closed at $95.77 at the end of the last trading period.
  4. Citigroup upgraded the previous rating for Mirati Therapeutics Inc MRTX from Neutral to Buy. For the first quarter, Mirati Therapeutics had an EPS of $2.67, compared to year-ago quarter EPS of $2.02. The current stock performance of Mirati Therapeutics shows a 52-week-high of $249.42 and a 52-week-low of $91.90. Moreover, at the end of the last trading period, the closing price was at $154.86.
  5. For Wells Fargo & Co WFC, B of A Securities upgraded the previous rating of Neutral to Buy. Wells Fargo earned $1.05 in the first quarter, compared to $0.80 in the year-ago quarter. The current stock performance of Wells Fargo shows a 52-week-high of $48.13 and a 52-week-low of $20.76. Moreover, at the end of the last trading period, the closing price was at $46.46.
  6. According to Wells Fargo, the prior rating for Bank OZK OZK was changed from Equal-Weight to Overweight. Bank OZK earned $1.11 in the first quarter, compared to $0.09 in the year-ago quarter. The stock has a 52-week-high of $45.83 and a 52-week-low of $20.10. At the end of the last trading period, Bank OZK closed at $42.95.
  7. William Blair upgraded the previous rating for Inogen Inc INGN from Market Perform to Outperform. Inogen earned $0.03 in the first quarter, compared to $0.07 in the year-ago quarter. The stock has a 52-week-high of $69.00 and a 52-week-low of $26.57. At the end of the last trading period, Inogen closed at $59.49.
  8. For Penumbra Inc PEN, BTIG upgraded the previous rating of Neutral to Buy. In the first quarter, Penumbra showed an EPS of $0.27, compared to $0.00 from the year-ago quarter. At the moment, the stock has a 52-week-high of $314.22 and a 52-week-low of $163.48. Penumbra closed at $256.66 at the end of the last trading period.
  9. Stifel upgraded the previous rating for Northrop Grumman Corp NOC from Hold to Buy. In the first quarter, Northrop Grumman showed an EPS of $6.57, compared to $5.15 from the year-ago quarter. At the moment, the stock has a 52-week-high of $378.61 and a 52-week-low of $282.88. Northrop Grumman closed at $366.51 at the end of the last trading period.
  10. UBS upgraded the previous rating for United States Steel Corp X from Sell to Neutral. United States Steel earned $1.08 in the first quarter, compared to $0.73 in the year-ago quarter. The current stock performance of United States Steel shows a 52-week-high of $29.97 and a 52-week-low of $6.58. Moreover, at the end of the last trading period, the closing price was at $25.89.

See all analyst ratings upgrades.

 

Downgrades

  • According to Wolfe Research, the prior rating for ArcBest Corp ARCB was changed from Outperform to Peer Perform. ArcBest earned $1.01 in the first quarter, compared to $0.36 in the year-ago quarter. At the moment, the stock has a 52-week-high of $93.96 and a 52-week-low of $22.18. ArcBest closed at $76.87 at the end of the last trading period.
  • B of A Securities downgraded the previous rating for Alliance Data Systems Corp ADS from Buy to Neutral. In the first quarter, Alliance Data Systems showed an EPS of $6.28, compared to $0.75 from the year-ago quarter. At the moment, the stock has a 52-week-high of $128.16 and a 52-week-low of $38.88. Alliance Data Systems closed at $122.82 at the end of the last trading period.
  • For Pentair PLC PNR, Morgan Stanley downgraded the previous rating of Equal-Weight to Underweight. Pentair earned $0.81 in the first quarter, compared to $0.52 in the year-ago quarter. The current stock performance of Pentair shows a 52-week-high of $70.76 and a 52-week-low of $35.61. Moreover, at the end of the last trading period, the closing price was at $69.57.
  • Cowen & Co. downgraded the previous rating for Workhorse Group Inc WKHS from Outperform to Market Perform. Workhorse Group earned $1.04 in the first quarter, compared to $0.07 in the year-ago quarter. At the moment, the stock has a 52-week-high of $42.96 and a 52-week-low of $2.73. Workhorse Group closed at $14.77 at the end of the last trading period.
  • According to Truist Securities, the prior rating for AvalonBay Communities Inc AVB was changed from Buy to Hold. In the first quarter, AvalonBay Communities showed an EPS of $1.95, compared to $2.39 from the year-ago quarter. The current stock performance of AvalonBay Communities shows a 52-week-high of $213.67 and a 52-week-low of $131.38. Moreover, at the end of the last trading period, the closing price was at $213.10.
  • Jefferies downgraded the previous rating for Grocery Outlet Holding Corp GO from Buy to Hold. In the first quarter, Grocery Outlet Holding showed an EPS of $0.23, compared to $0.36 from the year-ago quarter. The current stock performance of Grocery Outlet Holding shows a 52-week-high of $48.87 and a 52-week-low of $31.81. Moreover, at the end of the last trading period, the closing price was at $34.43.
  • Jefferies downgraded the previous rating for Constellation Pharmaceuticals Inc CNST from Buy to Hold. Constellation earned $0.84 in the first quarter, compared to $0.61 in the year-ago quarter. The current stock performance of Constellation shows a 52-week-high of $40.84 and a 52-week-low of $17.00. Moreover, at the end of the last trading period, the closing price was at $33.84.

See all analyst ratings downgrades.

 

Initiations

  • With a Buy rating, Colliers Securities initiated coverage on Performant Financial Corp PFMT. The price target seems to have been set at $10.00 for Performant Financial. In the first quarter, Performant Financial showed an EPS of $0.05, compared to $0.04 from the year-ago quarter. The current stock performance of Performant Financial shows a 52-week-high of $4.12 and a 52-week-low of $0.55. Moreover, at the end of the last trading period, the closing price was at $4.11.
  • Citigroup initiated coverage on 9 Meters Biopharma Inc NMTR with a Buy rating. The price target for 9 Meters Biopharma is set to $3.00. 9 Meters Biopharma earned $0.03 in the first quarter, compared to $0.09 in the year-ago quarter. The stock has a 52-week-high of $2.26 and a 52-week-low of $0.45. At the end of the last trading period, 9 Meters Biopharma closed at $1.29.
  • With an Overweight rating, Cantor Fitzgerald initiated coverage on Cerecor Inc CERC. The price target seems to have been set at $7.00 for Cerecor. For the first quarter, Cerecor had an EPS of $0.32, compared to year-ago quarter EPS of $0.36. At the moment, the stock has a 52-week-high of $4.50 and a 52-week-low of $1.98. Cerecor closed at $2.73 at the end of the last trading period.
  • Alliance Global Partners initiated coverage on TRACON Pharmaceuticals Inc TCON with a Buy rating. The price target for TRACON Pharmaceuticals is set to $13.00. For the first quarter, TRACON Pharmaceuticals had an EPS of $0.33, compared to year-ago quarter EPS of $0.78. The stock has a 52-week-high of $12.20 and a 52-week-low of $1.55. At the end of the last trading period, TRACON Pharmaceuticals closed at $6.10.
  • With an Outperform rating, Baird initiated coverage on Cerence Inc CRNC. The price target seems to have been set at $122.00 for Cerence. For the second quarter, Cerence had an EPS of $0.69, compared to year-ago quarter EPS of $0.43. The stock has a 52-week-high of $139.00 and a 52-week-low of $34.23. At the end of the last trading period, Cerence closed at $101.58.
  • With a Buy rating, UBS initiated coverage on Extra Space Storage Inc EXR. The price target seems to have been set at $168.00 for Extra Space Storage. For the first quarter, Extra Space Storage had an EPS of $1.50, compared to year-ago quarter EPS of $1.24. The stock has a 52-week-high of $154.31 and a 52-week-low of $88.88. At the end of the last trading period, Extra Space Storage closed at $153.78.
  • UBS initiated coverage on Regency Centers Corp REG with a Neutral rating. The price target for Regency Centers is set to $66.00. Regency Centers earned $0.90 in the first quarter, compared to $0.98 in the year-ago quarter. The current stock performance of Regency Centers shows a 52-week-high of $67.59 and a 52-week-low of $33.29. Moreover, at the end of the last trading period, the closing price was at $66.81.
  • With a Buy rating, Goldman Sachs initiated coverage on Avantor Inc AVTR. The price target seems to have been set at $40.00 for Avantor. Avantor earned $0.35 in the first quarter, compared to $0.17 in the year-ago quarter. At the moment, the stock has a 52-week-high of $33.99 and a 52-week-low of $16.37. Avantor closed at $30.68 at the end of the last trading period.
  • With a Neutral rating, Goldman Sachs initiated coverage on Twist Bioscience Corp TWST. The price target seems to have been set at $110.00 for Twist Bioscience. In the second quarter, Twist Bioscience showed an EPS of $0.78, compared to $0.85 from the year-ago quarter. At the moment, the stock has a 52-week-high of $214.07 and a 52-week-low of $35.50. Twist Bioscience closed at $96.12 at the end of the last trading period.
  • Goldman Sachs initiated coverage on Quanterix Corp QTRX with a Sell rating. The price target for Quanterix is set to $53.00. In the first quarter, Quanterix showed an EPS of $0.29, compared to $0.41 from the year-ago quarter. The stock has a 52-week-high of $92.57 and a 52-week-low of $24.22. At the end of the last trading period, Quanterix closed at $53.56.
  • Piper Sandler initiated coverage on Shift Technologies Inc SFT with an Overweight rating. The price target for Shift Technologies is set to $14.00. In the first quarter, Shift Technologies earned $0.55. The current stock performance of Shift Technologies shows a 52-week-high of $12.34 and a 52-week-low of $6.17. Moreover, at the end of the last trading period, the closing price was at $7.43.
  • With a Buy rating, HC Wainwright & Co. initiated coverage on Protara Therapeutics Inc TARA. The price target seems to have been set at $40.00 for Protara Therapeutics. In the first quarter, Protara Therapeutics showed an EPS of $1.20, compared to $1.81 from the year-ago quarter. At the moment, the stock has a 52-week-high of $67.08 and a 52-week-low of $8.54. Protara Therapeutics closed at $9.26 at the end of the last trading period.
  • HC Wainwright & Co. initiated coverage on Yumanity Therapeutics Inc YMTX with a Buy rating. The price target for Yumanity Therapeutics is set to $39.00. Yumanity Therapeutics earned $0.85 in the first quarter, compared to $3.47 in the year-ago quarter. The current stock performance of Yumanity Therapeutics shows a 52-week-high of $23.47 and a 52-week-low of $13.52. Moreover, at the end of the last trading period, the closing price was at $15.20.
  • With an Outperform rating, Oppenheimer initiated coverage on Windtree Therapeutics Inc WINT. The price target seems to have been set at $8.00 for Windtree Therapeutics. In the first quarter, Windtree Therapeutics showed an EPS of $0.51, compared to $0.48 from the year-ago quarter. The stock has a 52-week-high of $10.06 and a 52-week-low of $1.58. At the end of the last trading period, Windtree Therapeutics closed at $1.98.
  • With a Buy rating, HC Wainwright & Co. initiated coverage on C4 Therapeutics Inc CCCC. The price target seems to have been set at $63.00 for C4 Therapeutics. C4 Therapeutics earned $0.49 in the first quarter. The current stock performance of C4 Therapeutics shows a 52-week-high of $48.98 and a 52-week-low of $22.40. Moreover, at the end of the last trading period, the closing price was at $38.15.

See all analyst ratings initiations.

Posted In: BZI-RatingsUpgradesDowngradesInitiationIntraday UpdateAnalyst Ratings

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.